Bladder Cancer

Effectiveness of Preoperative Immunonutrition in Improving Surgical Outcomes after Radical Cystectomy for Bladder Cancer: Study Protocol for a Multicentre, Open-Label, Randomised Trial (INu-RC).

Radical cystectomy (RC) with pelvic lymph node dissection is the standard treatment for patients with limited-stage muscle-invasive bladder cancer. RC is associated with a complication rate of approximately 50-88%.

The Effect of Retinoic Acid on Arsenite-Transformed Malignant UROtsa Bladder Cancer Cells: In Vitro Model of Basal Muscle-Invasive Bladder Cancer.

Bladder cancer (BC) is the eighth most common cause of cancer death in the United States of America. BC is classified into non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC).

Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy

Reno, Nevada (UroToday.com) -- Oslo, Norway: Photocure ASA, The Bladder Cancer Company, announces the publication of the study “Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy: Insights from a Multicenter Registry” in the journal Cancers this week. This study aims to evaluate heterogeneity in characteristics of blue light cystoscopy (BLC®) for the detection of malignant lesions among various races with non‐muscle invasive bladder cancer (NMIBC).

Preliminary findings on the development of a predictive model for BLCA based on disulfidptosis-associated IncRNAs signature.

Bladder urothelial carcinoma (BLCA) is the most common malignancy of the urinary tract, presenting with a wide range of clinical symptoms and prognosis. Disulfidptosis is a newly identified cell death method and closely associated with BLCA progression, prognosis, and treatment outcome.

Quantitative differentiation of non-invasive bladder urothelial carcinoma and inverted papilloma based on CT urography.

To investigate the value of CT urography (CTU) indicators in the quantitative differential diagnosis of bladder urothelial carcinoma (BUC) and inverted papilloma of the bladder (IPB).

The clinical and preoperative CTU imaging data of continuous 103 patients with histologically confirmed BUC or IPB were retrospectively analyzed.

Initial Experience with 68Ga-FAP-2286 PET Imaging in Patients with Urothelial Cancer - Beyond the Abstract

Localized muscle invasive bladder cancer (MIBC), if identified early in a patient’s disease course, can be cured in a significant fraction of patients through a combination of neoadjuvant systemic therapy followed by radical cystectomy. On the other hand, patients with metastatic bladder cancer have a drastically different treatment paradigm and undergo systemic treatment without local intervention.

The effect of enhanced recovery after surgery on oncologic outcome following radical cystectomy for urothelial bladder carcinoma.

Limited data are available regarding the effect of enhanced recovery after surgery (ERAS) protocols on the long-term outcomes of radical cystectomy (RC) in bladder cancer patients. The aim of this study is to evaluate the oncological outcomes in patients who underwent RC with ERAS protocol.

Antibiotic therapy impact on intravesical BCG therapy efficacy for high-risk localized bladder cancer treatment.

Intravesical Bacillus Calmettes-Guerin (BCG) instillations is the gold standard adjuvant treatment for high and very high-risk non-muscle-invasive bladder cancer (NMIBC). Antibiotics may be required to treat asymptomatic bacteriuria before instillations or to prevent side effects.

Urine Tumor DNA-Informed Analysis of ctDNA in Patients with Muscle-Invasive Bladder Cancer - Expert Commentary

The presence of circulating tumor DNA (ctDNA) in patients with muscle-invasive bladder cancer (MIBC) is indicative of relapse and worsening prognosis. Due to the practical barriers to sequencing tumor samples for ctDNA measurement, medical researchers have focused efforts on developing alternative assays. BinHumaid et al. describe novel approaches to ctDNA detection using blood serum and urine. The technique relies on combining measurements made in small volumes of serum with a gene panel that detects urinary tumor DNA (utDNA) which now includes both coding and non-coding mutation spots.

Dysregulated FGFR3 signaling alters the immune landscape in bladder cancer and presents therapeutic possibilities in an agent-based model.

Bladder cancer is an increasingly prevalent global disease that continues to cause morbidity and mortality despite recent advances in treatment. Immune checkpoint inhibitors (ICI) and fibroblast growth factor receptor (FGFR)-targeted therapeutics have had modest success in bladder cancer when used as monotherapy.

A Prognostic Index Derived From LASSO-Selected Preoperative Inflammation and Nutritional Markers for Non-Muscle-Invasive Bladder Cancer.

There is an urgent need to identify a robust predictor for BCG response in patients with non-muscle-invasive bladder cancer (NMIBC). We aimed to employ the Lasso regression model for the selection and construction of an index (BCGI) utilizing inflammation and nutrition indicators to predict the response to BCG therapy.

Racial Differences in the Detection Rate of Bladder Cancer Using Blue Light Cystoscopy: Insights from a Multicenter Registry

Simple Summary: Blue light cystoscopy (BLC) is a technique used to find bladder tumors more effectively. However, its performance across different races remains uncertain. In this study, we looked at how well BLC detects cancer in people of different races. We collected data from patients who had bladder tumor surgeries from 2014 to 2021. Overall, we found that BLC was better at spotting tumors compared to traditional white light cystoscopy (WLC). This was true for most races, especially for Caucasian and Asian patients. When BLC was added to WLC, it increased the detection of cancer by 10%, with the biggest improvement seen in Asian patients. Interestingly, Asian patients had the highest chance of BLC correctly identifying cancer, while Hispanic patients had the best chance of ruling out cancer. This suggests that combining BLC with WLC can improve the detection of bladder cancer irrespective of race.

Longitudinal Tumor-informed Circulating Tumor DNA Status Predicts Disease Upstaging and Poor Prognosis for Patients Undergoing Radical Cystectomy.

Decision-making on the use of neoadjuvant and adjuvant treatment for patients with bladder cancer undergoing radical cystectomy (RC) currently depends on assessment of clinical and pathological features, which lack sensitivity.

Identifying the supportive care needs of people affected by non-muscle invasive bladder cancer: An integrative systematic review.

To understand supportive care needs among people with non-muscle invasive bladder cancer (NMIBC).

An integrative systematic review was reported using the Preformed Reporting Items for Systematic Review and Meta-analyses (PRISMA) guidelines.

Current Trends and Challenges of Microbiome Research in Bladder Cancer - Beyond the Abstract

Microbiome research is revolutionizing medical care by elucidating the intricate relationship between bacteria and human health, creating an opportunity for novel and personalized care.

Determining the clinicopathological significance of the VI-RADS ≧4 group: a retrospective study.

The Vesical Imaging Reporting and Data System (VI-RADS) is widely used for predicting muscle-invasive bladder cancer (MIBC). This study aimed to determine the clinicopathological significance of the VI-RADS ≧4 (VI≧4) group.

The effect of race/ethnicity on cancer-specific mortality after trimodal therapy.

Trimodal therapy (TMT) is the most validated bladder-sparing treatment for organ-confined urothelial carcinoma of the urinary bladder (OC UCUB, namely cT2N0M0). However, it is unknown if barriers to the use of TMT or cancer-specific mortality (CSM) differences exist according to race/ethnicity.

A Genomic Urine Assay for Surveillance of Patients with Bladder Cancer Treated with Radiotherapy.

Patients with muscle-invasive bladder cancer (MIBC) who receive radiotherapy with curative intent are followed by imaging, cystoscopy, and urine cytology. However, interpretation of cytology and cystoscopy is hampered by the impact of ionizing radiation on cells.

Performance of VI-RADS in predicting muscle-invasive bladder cancer after transurethral resection: a single center retrospective analysis.

To assess VIRADS performance and inter-reader agreement for detecting muscle-invasive bladder cancer (MIBC) following transurethral resection of bladder tumor (TURBT).

An IRB-approved, HIPAA-compliant, retrospective study from 2016 to 2020 included patients with bladder urothelial carcinoma who underwent MRI after TURBT, and cystectomy within 3 months without post-MRI treatments.

Quality of Life after Definitive Treatment for Bladder Cancer: A Systematic Review and Meta-Analysis - Beyond the Abstract

The pursuit of enhanced quality of life represents a pivotal endpoint after the radical treatment of muscle-invasive bladder cancer. Information about this specific facet assumes paramount significance, as it holds the potential to significantly shape patients' perspectives regarding the management of their ailment. Radical cystectomy, a common therapeutic intervention, is frequently associated with a considerable impact on the overall quality of life. In response to this challenge, alternative methods that aim to preserve continence, such as continent cutaneous urinary diversion and orthotopic neobladder, have been proposed as viable treatment options to ameliorate patients' reported outcomes post-treatment.